Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon.
OBJECTIVE
In the intestine, tachykinins regulate motility by participating in neuromuscular and neuro-neuronal transmission. The aim of this study was to test the hypothesis that colonic propulsion is regulated by an interplay between tachykinergic and cholinergic transmission.


METHODS
Propulsion was elicited by intraluminal distention of a thin rubber balloon, which traveled from the oral to the anal end of guinea pig isolated distal colon segments. The overall contribution of endogenous tachykinins to colonic propulsion was examined by blocking NK1, NK2, and NK3 receptors simultaneously.


RESULTS
NK2-receptor blockade by MEN 11420 inhibited propulsion, whereas blockade of NK(1) by SR 140333 or of NK3 receptors by SR 142801 had minor effects on motility. Blockade of muscarinic or nicotinic receptors by hyoscine or hexamethonium decelerated peristalsis up to propulsion arrest. In the presence of partial muscarinic receptor blockade, the NK1-receptor antagonist SR 140333 and the NK2-receptor antagonist MEN 11420 markedly inhibited propulsion. Propulsion was also inhibited by the NK3-receptor antagonist SR 142801 in the presence of partial nicotinic receptor blockade. The simultaneous administration of the 3 tachykinin antagonists inhibited propulsion by 50%.


CONCLUSIONS
This study demonstrates the existence of an interplay between tachykinergic and cholinergic pathways during peristalsis and the importance of endogenous tachykinins acting at multiple receptor sites in the control of colonic propulsion.
Tonini
M
M
Department of Internal Medicine and Therapeutics, Division of Clinical and Experimental Pharmacology, University of Pavia, Italy. tonini@unipv.it
Spelta
V
V
De Ponti
F
F
De Giorgio
R
R
D'Agostino
G
G
Stanghellini
V
V
Corinaldesi
R
R
Sternini
C
C
Crema
F
F
D000818:Animals; D003106:Colon / Q000187:drug effects / Q000502:physiology*; D004338:Drug Combinations; D018738:Hexamethonium / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010528:Peristalsis / Q000187:drug effects / Q000502:physiology*; D010880:Piperidines / Q000494:pharmacology; D011812:Quinuclidines / Q000494:pharmacology; D012601:Scopolamine / Q000494:pharmacology; D015320:Tachykinins / Q000037:antagonists & inhibitors / Q000502:physiology*
D004338:Drug Combinations; C107754:MEN 11420; D018727:Muscarinic Antagonists; D018733:Nicotinic Antagonists; D010456:Peptides, Cyclic; D010880:Piperidines; D011812:Quinuclidines; D015320:Tachykinins; C085215:SR 140333; D018738:Hexamethonium; D012601:Scopolamine; C091554:SR 142801